HER2+ Breast Cancer | Specialty

FDA Grants Pertuzumab Priority Review for HER2+ Early Breast Cancer

September 29th 2017

The FDA has granted a priority review to a supplemental biologics license application for pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Cleveland Clinic Researcher Recaps Successes and Stumbles in Dual HER2 Targeting

September 25th 2017

Although dual HER2 blockade strategies have become an important part of the treatment paradigm for patients with HER2-positive breast cancer, the complexities of administering these therapies continue to unfold.

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer

September 17th 2017

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

September 8th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

September 7th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Finding the Right Place for Dual HER2 Blockade in Breast Cancer and Beyond

September 4th 2017

Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.

Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

September 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer

August 31st 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

FDA Delays Decision on Trastuzumab Biosimilar MYL-1401O

August 30th 2017

The FDA has extended its decision deadline by 3 months on a biologics license application for MYL-1401O, a trastuzumab biosimilar co-developed by Mylan and Biocon. A final decision is expected on or before December 3, 2017.

FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer

August 30th 2017

The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer.

Liquid Biopsy for NSCLC: Emerging Developments

August 29th 2017

Future Directions for Liquid Biopsy in NSCLC

August 29th 2017

Liquid Biopsy and Next-Generation Sequencing

August 29th 2017

Interpretation of NSCLC Plasma Genotyping Results

August 29th 2017

Liquid Biopsy: Differences Among Technologies

August 29th 2017

Plasma Genotyping Platforms: Strengths and Limitations

August 29th 2017

Plasma Testing for NSCLC EGFR & ALK Mutations

August 29th 2017

Clinical Applications for NSCLC Liquid Biopsy

August 29th 2017

How Does Liquid Biopsy Work?

August 29th 2017

The Role for Liquid Biopsy in NSCLC

August 29th 2017